Arrhythmias & electrophysiology
Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug
Main finding · AF incidenceResult — go to the resultHazard ratio 0.59 95% CI 0.53–0.67Authors' conclusion
Our study, performed in a subset of the Italian CCS population, showed that Ran therapy was safe and associated with a long-term reduced AF incidence.
Study context
- Population
- Italian patients with chronic coronary syndrome hospitalized 2011–2020, without prior atrial fibrillation (AF)matched: Ranolazine (Ran) 6384, No-Ran 25,536
- Participants
- 171,015 patients
- Exposure
- Ranolazine add-on vs no ranolazine
- Rann = 6,384
- No-Rann = 25,536reference
- Outcome
- Incidence of AF
- Follow-up
- 4.4 (Ran) and 5.0 (No-Ran) years
Methodological detailspropensity-score matched, Italian National Health System databases
- Propensity-score matched
- Italian National Health System databases
Main finding
AF incidence
Hazard ratio
0.59
95% CI 0.53–0.67
P < 0.001
By group
Ranvs No-Ran
HR 0.59 (95% CI 0.53–0.67); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Reduced incidence of brady-arrhythmias with Ran
- P = 0.001
- Reduced incidence of ventricular tachy-arrhythmias with Ran
- P = 0.049
- Lower mortality with Ran
- P < 0.001
Original publication
Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug. Eur Heart J Cardiovasc Pharmacother. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →